

## PE Human OX40 (CD134) Protein (C-Fc-Avi)

|                           |                                      |
|---------------------------|--------------------------------------|
| <b>Catalog Number:</b>    | 818201, 818202                       |
| <b>Size:</b>              | 25 ug, 100 ug                        |
| <b>Target Name:</b>       | TNFRSF4, OX40, CD134, OX40L receptor |
| <b>Regulatory Status:</b> | RUO                                  |

### PRODUCT DETAILS

---

|                               |  |
|-------------------------------|--|
| <b>Application:</b>           | Flow Cytometry   |
| <b>Format:</b>                | Liquid, PE   |
| <b>Expression Host:</b>       | CHO  |
| <b>Species:</b>               | Human  |
| <b>Sources:</b>               | Recombinant Human OX40 (Lue29-Ala216 ) with C-terminus Fc-Avi-tag is expressed in CHO cell and conjugated to PE.   |
| <b>Accession Number:</b>      | P43489   |
| <b>Molecular Weight:</b>      | The protein has a predicted molecular weight of 48.5 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE prior to conjugation. |
| <b>Affinity Tag:</b>          | C-Fc-Avi   |
| <b>Formulation:</b>           | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein   |
| <b>Endotoxin level:</b>       | Not tested   |
| <b>Protein Concentration:</b> | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.  |
| <b>Storage and Handling:</b>  | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2-8°C for up to six months.  |

### BACKGROUND INFORMATION

---

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.